MaxCyte Announces Retirement of Board Member Art Mandell
23. Dezember 2024 02:00 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
09. Dezember 2024 02:00 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
13. November 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
06. November 2024 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte to Participate in Two Upcoming Investor Conferences
31. Oktober 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Appoints Cynthia Collins to its Board of Directors
15. Oktober 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
11. Oktober 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
10. Oktober 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
16. September 2024 02:00 ET
|
MaxCyte, Inc
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform...
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
05. September 2024 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...